NuBloom review

A women's-health telehealth brand that prices four treatment routes side by side on one page, which makes cross-shopping genuinely easy, and sells the microdose as an explicitly separate product beneath the full-dose figure. Everything behind those numbers is missing: no milligram, no dose ladder, no plan length, and every figure is a starting-at price, so the gap between the two is the only thing that distinguishes a microdose from a full dose here. Its own FAQ contradicts the compounded-drug disclosure printed on the same page, and prescribing is delegated to a third party it does not name as its own.

Vs median

$80/mo above the $169 median across the 242 of 373 programs we track that publish a plain monthly rate

Market

$59–$1300/mo is the full published spread in our ranking

Structure

Charges less for less

Consult

Included in the price

Dietitian

Not included

Labs

Optional

Pricing

Varies by dose, plan or tier

Price last updated

August 2026

NuBloom does not publicly identify the pharmacy that fills its prescriptions. Bloodwork is offered but not required. A clinician review is included in the price.

NuBloom is a women's-health-branded telehealth and supplement brand with a direct-to-consumer supplement store sold on-site and prescription care handed off to a separate patient portal. Prescribing and provider access run through a third-party telehealth organization the footer describes as LegitScript-certified; NuBloom itself names no physician and no pharmacy. Its GLP-1 line is listed on one page as four price points — semaglutide, tirzepatide, microdose tirzepatide and a non-GLP-1 combination — with no dose, ladder or plan detail. A 90-day coaching program adds weekly 1:1 coaching, monthly provider visits and lab assessments. Its states page lists 49 states.

Every GLP-1 figure is a "starting at" price with no milligram, no ladder and no plan length — the $249 microdose could buy any quantity of drug, and nothing on the site narrows it

• The FAQ states that NuBloom prescribes FDA-approved weight-loss medications including GLP-1s, which directly contradicts the compounded-drug disclosure printed on the same page
• It misspells its own product name on the only page that prices it, while spelling the full-dose product correctly two lines above
• No legal entity, no named prescriber and no pharmacy is identified anywhere — prescribing is delegated to a third party
• The public product catalog still contains a live automated-testing placeholder product
• No GLP-1 price can be confirmed at checkout: the prescription funnel sits behind a portal that returns an empty shell
• Compounded GLP-1s are not FDA-approved, and intentional microdosing is off-label and unproven

NuBloom is one of 373 low-dose GLP-1 programs we track, and 242 of them publish a monthly rate you can read before signing up. The ranking lists every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• Microdosing tirzepatide
• Is compounded GLP-1 safe?
• What a flat price costs at a low dose
• Microdose & reconstitution calculator